The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has named Rachel Myslinski, MBA, as Chief Executive Officer (CEO). Myslinski is a senior executive with more than 20 years of experience in healthcare in the professional medical association, management consulting, and non-profit research foundation settings. She brings deep expertise in executive leadership, strategic planning, non-profit Board …
Use of Extrapolation to Support Regulatory Decision-Making Discussed (Washington, DC – August 4, 2023) – Findings from a recent stakeholder workshop on the development of therapeutics for polyarticular JIA (pJIA) were published online in the April 27, 2023 issue of Arthritis & Rheumatology. The report, “Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA): Extrapolation, …
The Arthritis Foundation and the Childhood Arthritis and Rheumatology Research Alliance (CARRA) announce the recipients of almost $1.2 million in research funding for pediatric rheumatic diseases. Read the full press release at arthritis.org.
WASHINGTON, DC, December 6, 2022 – The Childhood Arthritis and Rheumatology Research Alliance, also known as CARRA, announced the appointment of Mathieu Nelessen as Chief Executive Officer, effective January 9, 2023. The CARRA Board of Directors unanimously approved the recommendation of Mr. Nelessen by a CARRA CEO search task force, which led a three-month nationwide …
Lupus Advocacy Efforts Drive Research Funding for the CARRA Registry. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) announced that the U.S. Centers for Disease Control and Prevention (CDC) awarded a 5-year $4.4 million grant to a team of North American lupus experts to advance critical research on childhood lupus through the CARRA Registry. Read …
Arthritis Foundation and CARRA Fund $1.1+ Million for Childhood Rheumatic Disease Research The Arthritis Foundation and the Childhood Arthritis and Rheumatology Research Alliance (CARRA) announce more than $1.1 million in research funding for childhood rheumatic diseases, including juvenile idiopathic arthritis. Read the full press release at arthritis.org
CARRA announced the hiring of Interim CEO Larry Hausner on January 28, 2022. We recently visited with Larry to learn a little more about his leadership experiences and how he will support CARRA’s journey throughout 2022. Q: Please share with CARRA stakeholders and followers a little about your background. Larry: For most of the past …